Drug Profile
NYVAC C
Alternative Names: NYVAC poxvirus vector + clade C gag-pol-nef + env immunogen; NYVAC-HIV-CLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator EuroVacc Foundation; GENEART; sanofi pasteur; University of Regensburg
- Developer EuroVacc Foundation
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 21 Sep 2015 No recent reports on development identified - Phase-I/II for HIV-1 infections (Prevention) in Switzerland, United Kingdom, France (IM)
- 13 Apr 2010 The vaccine is still in active development
- 23 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the adverse events section